Go to content Go to navigation

ACR Special Report: Chicago, IL 2011

References

i Houssiau FA, et al. Active Immunization Against IFN with IFN-Kinoid in SLE Patients Is Safe, Immunogenic and Induces Down-Regulation of IFN-Mediated Genes. Abstract 2470.
ii Wallace DJ, et al. Safety Profile of Belimumab, a B-Lymphocyte Stimulator–Specific Inhibitor, in Phase 2 and 3 Clinical Trials of Patients with Active Systemic Lupus Erythematosus. Abstract 578
iii Merrill JT, et al. Sustained Disease Improvement and Safety Profile Over the 1500 Patient-Year Experience (6 years) with Belimumab in Patients with Systemic Lupus Erythematosus. Abstract 584.
iv Van Vollenhoven RF, et al. Factors Associated with Belimumab Treatment Benefit: Results From Phase 3 Studies in Patients with Systemic Lupus Erythematosus. Abstract 1416.
v Strand V. Responders in the Phase 3 Belimumab Clinical Trials in Patients with Systemic Lupus Erythematosus Reported Improvements in Fatigue and Health-Related Quality of Life At Week 52. Abstract 1369.
vi Furie R, et al. Efficacy and Safety of Abatacept Over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study. Abstract 2469.
vii Wofsy D, et al. Abatacept for Lupus Nephritis: Alternative Outcome Measures Support Opposing Interpretations of Data From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study. Abstract 2474.
viii Szepietowski JC, et al. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple, Intravenous, Ascending-Dose Study of Sirukumab in Patients with Cutaneous or Systemic Lupus Erythematosus. Abstract 1268.
ix Olferiev M. Analysis of Longitudinal Gene and Protein Expression Data Classifies SLE Patients Based on Molecular Profiles Associated with Disease Activity, Serology and Specific Organ Manifestations. Abstract 1424.
x Buyon JP, et al. Favorable Prognosis in a Large, Prospective Multicenter Study of Lupus Pregnancies. Abstract 1717.
xi Terrier et al. Restoration of Regulatory T Cells-Th17 Cells Balance in Systemic Lupus Erythematosus Through Vitamin D Supplementation. Abstract 577.
xii Van Vollenhoven RF, et al. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS). Abstract 609.
xiii Weckerle CE. Large Scale Analysis of Serum Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus. Abstract 1429.
xiv Morrison S, et al. Status and Missing Days At Work in a Large Population of Patients with Systemic Lupus Erythematosus (SLE). Abstract 2273.
xv Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum. 2010;62(5):1478-86.
xvi Antonchak MA, Saoudian M, Khan AR, Brunner HI, Luggen ME. J Rheumatol. 2011;38(6):1020-5.
xvii McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005 Jan 25;64(2):297-303.


More information about lupus and treatment advances can be found by visiting www.lupusresearch.org.

The Alliance for Lupus Research Special Report on the 2011 American College of Rheumatology Meeting was made possible in part by generous support from Genentech.

Genetech

©2011 Alliance for Lupus Research. All Rights Reserved.

Contents herein may not be reproduced, republished or distributed without the prior written permission of the Alliance for Lupus Research. To request permission to reproduce, republish or distribute any part of this report, contact us at 212-218-2840 or email info@lupusresearch.org.


Share this page...